Surf Therapeutics Secures Seed Extension to Advance Ultrasound Neuromodulation Platform

There is a certain kind of company that doesn’t make noise, it makes signals. Surf Therapeutics is one of those. Built in Austin, moving with intent since late 2022, and now sitting on roughly $6M in total funding after a seed extension that kept the cap table tight and the story tighter. No theatrics, just progress that shows up in data and discipline.

Let’s talk about that data. A first-in-human study, 14 participants, multi-center, controlled, and clean. Statistically significant reductions in TNF-α and IL-6. No device-related adverse events. In biotech, that’s not a headline, that’s a door quietly unlocking. The kind that separates theory from something you can actually build a company on.

Nishant Doctor, co-founder and CEO, has been steering this with a calm hand and a sharp eye. You can feel it in the pacing. Preclinical to human trials to an active Early Feasibility Study enrolling up to 40 patients across Dallas-Fort Worth. That’s not luck, that’s sequencing. The kind of sequencing most people only appreciate after they miss it.

Surf Therapeutics isn’t chasing inflammation with another molecule. They’re going upstream, using non-invasive ultrasound neuromodulation to tap the body’s own anti-inflammatory pathways. No drugs, no implants, no surgical theater. Just signal in, response out. If that sounds simple, it’s because the hard part is already happening under the hood.

The SUSTAIN platform is designed for something bigger than a clinical win. It’s built for scale, for repeatability, for the kind of at-home accessibility that turns treatment into routine instead of disruption. That matters in rheumatoid arthritis, where the burden isn’t just biological, it’s logistical.

The investor bench tells its own story. SOSV, VVP Ignite, TMC Venture Fund, General Inception, Elderberry Ventures, Evoce Capital, and operators like Joe Kiani and Mir Imran leaning in. That’s not tourist capital. That’s people who know what it takes to move from promising to proven without burning the clock or the cash.

And here’s the quiet lesson sitting underneath all of it. Capital didn’t create momentum here. Momentum pulled in capital. Clinical signal, tight execution, and a clear path to a pivotal study tend to do that. Funny how discipline compounds faster than hype.